Search results
We’re on the road with a new approach to clinical trials—one that expands access to cutting-edge medicines and treatments. Lilly is a medicine company turning science into healing to make life better for people around the world.
3 days ago · Lilly officials said 2% of people who received donanemab during the study died compared with 1.7% of people who received a placebo. Several panel members questioned Eli Lilly experts about the ...
We’re a medicine company turning science into healing to make life better for people around the world. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges.
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
3 days ago · 01:48 - Source: CNN. CNN —. On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to ...
For more than 145 years, we have worked tirelessly to develop and deliver trusted medicines and diagnostics that meet real needs. Our growing portfolio of medicines includes treatments in the areas of bone muscle joint, cancer, cardiovascular, diabetes, endocrine, immunology, neuroscience and obesity. The product information on this website is ...
3 days ago · June 10, 2024 at 4:53 p.m. EDT. The Eli Lilly drug, donanemab, works by clearing a sticky plaque from the brain. (Mike Blake/Reuters) 5 min. An advisory committee to the Food and Drug ...
4 days ago · A committee of independent advisers to the F.D.A. voted unanimously that the benefits outweigh the risks of donanemab, the newest experimental drug made by Eli Lilly for Alzheimer’s disease. A ...
6 days ago · The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. May 13, 2022. Download PDF. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
